Protein (3)
Launched (3)
Human (1)Mouse (1)Cynomolgus (1)
His Tag (3)
Unconjugated (3)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT IT1-H52W3 | HEK293 | Human Integrin alpha 11 beta 1 (ITGA11&ITGB1) Heterodimer Protein, His Tag&Tag Free | ![]() | |||
HOT IT1-M52W5 | HEK293 | Mouse Integrin alpha 11 beta 1 (ITGA11&ITGB1) Heterodimer Protein, His Tag&Tag Free | ![]() | |||
CHO | Cynomolgus Integrin alpha 11 beta 1 (ITGA11&ITGB1) Heterodimer Protein, His Tag&Tag Free | ![]() |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| VVN-001 | VVN001; VVN-001 | Phase 3 Clinical | VivaVision Biotech Inc | Dry Eye Syndromes; Xerophthalmia | Details |
| P-28-R | P-28- R | Phase 1 Clinical | Canimguide Therapeutics | Head and Neck Neoplasms | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Odulimomab | Approved | Immunotech SAS | Antilfa | France | Graft vs Host Disease; Rejection of renal transplantation | null | 1997-01-01 | Rejection of renal transplantation; Graft vs Host Disease | Details |







